Lumbar fusion: rhBMP-2 reduces rate of fusion failure and reoperation .
Recombinant human bone morphogenetic protein-2 versus autogenous iliac crest bone graft for lumbar fusion: a meta-analysis of ten randomized controlled trials
Arch Orthop Trauma Surg. 2012 Dec;132(12):1725-40. doi: 10.1007/s00402-012-1607-3. Epub 2012 Sep 1This meta-analysis included 10 randomized controlled trials comparing recombinant human bone morphogenetic protein-2 (rhBMP-2) and iliac crest bone graft (ICBG) in patients receiving lumbar fusion. The results from the analysis indicated that the rate of fusion failure was significantly lower in the rhBMP-2 group than in the ICBG group at 6, 12, and 24 months. The rhBMP-2 group was also superior to the ICBG group in terms of the rate of reoperation. The two groups did not differ with respect to Oswestry disability index (ODI) scores.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
